Evidence map›Paper›PMID 41049759›Full record

ArticleActa pharmaceutica Sinica. B2025

Pleiotropic prodrugs for both symptomatic and disease-modifying treatment of Alzheimer's disease.

Anže Meden, Neža Žnidaršič, Damijan Knez, Yuanyuan Wang, Ziwei Xu, Huajing Yang, Weiting Zhang, Anja Pišlar, Andrej Perdih, Simona Kranjc Brezar and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anže MedenUniversity of Ljubljana, Faculty of Pharmacy, Ljubljana SI-1000, Slovenia.
Neža ŽnidaršičUniversity of Ljubljana, Faculty of Veterinary Medicine, Ljubljana SI-1000, Slovenia.
Damijan KnezUniversity of Ljubljana, Faculty of Pharmacy, Ljubljana SI-1000, Slovenia.
Yuanyuan WangChina Pharmaceutical University, Nanjing 210038, China.
Ziwei XuChina Pharmaceutical University, Nanjing 210038, China.
Huajing YangChina Pharmaceutical University, Nanjing 210038, China.
Weiting ZhangChina Pharmaceutical University, Nanjing 210038, China.
Anja PišlarUniversity of Ljubljana, Faculty of Pharmacy, Ljubljana SI-1000, Slovenia.
Andrej PerdihUniversity of Ljubljana, Faculty of Pharmacy, Ljubljana SI-1000, Slovenia.
Simona Kranjc BrezarDepartment of Experimental Oncology, Institute of Oncology, Ljubljana SI-1000, Slovenia.
Neža GrgurevičUniversity of Ljubljana, Faculty of Veterinary Medicine, Ljubljana SI-1000, Slovenia.
Stane PajkUniversity of Ljubljana, Faculty of Pharmacy, Ljubljana SI-1000, Slovenia.
Haopeng SunChina Pharmaceutical University, Nanjing 210038, China.
Stanislav GobecUniversity of Ljubljana, Faculty of Pharmacy, Ljubljana SI-1000, Slovenia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The inherent complexity of Alzheimer's disease (AD) and failed clinical trials have spiked the interest in multifunctional ligands that target at least two key disease-associated macromolecules in AD pathology. Here we present a focused series of pleiotropic

Indexed as

Alzheimer’s diseaseButyrylcholinesteraseCarbamatesDisease-modifying treatmentNeurodegenerative diseasesN-Heterocyclic ureasPleiotropic prodrugα2A adrenoreceptor

Identifiers

PMID41049759
PMCPMC12491715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.